2022 年第 5 期 第 17 卷

康艾注射液联合奥沙利铂加卡培他滨化疗方案治疗结肠癌患者的效果

Effect of Kang′ai injection combined with oxaliplatin and capecitabine chemotherapy on patients with colon cancer

作者：满其荣1袁倩倩2李培顺2杨森2章龙珍3

英文作者：Man Qirong1 Yuan Qianqian2 Li Peishun2 Yang Sen2 Zhang Longzhen3

单位：1徐州医科大学，徐州221004；2山东省滕州市中心人民医院肿瘤科，滕州277500；3徐州医科大学附属医院放射治疗科，徐州221002

英文单位：1Xuzhou Medical University Xuzhou 221004 China; 2Department of Oncology Tengzhou Central People′s Hospital Shandong Province Tengzhou 277500 China; 3Department of Radiotherapy the Affiliated Hospital of Xuzhou Medical University Xuzhou 221002 China

关键词：结肠癌；康艾注射液；奥沙利铂；卡培他滨

英文关键词：Coloncancer;Kang′aiinjection;Oxaliplatin;Capecitabine

• 摘要：

• 目的 探讨康艾注射液联合奥沙利铂+卡培他滨（CapeOX）化疗方案治疗结肠癌患者的效果及对血小板/淋巴细胞比值（PLR）、红细胞分布宽度（RDW）、中性粒细胞/淋巴细胞比值（NLR）水平的影响。方法 选取山东省滕州市中心人民医院肿瘤科2015年2月至2018年1月经病理学确诊的110例结肠癌患者，根据随机数字法将患者分为对照组（55例）和观察组（55例）。对照组采用CapeOX化疗方案治疗，观察组采用康艾注射液联合CapeOX化疗方案治疗。比较2组临床疗效、治疗前后PLR、RDW、NLR水平，毒副反应及随访2年后生存质量情况。结果 治疗后观察组客观缓解率、疾病控制率均明显高于对照组［49.1%(27/55)比27.3%(15/55)、81.8%(45/55)比63.6%(35/55)］，差异均有统计学意义（均P＜0.05）。治疗前2组患者PLR、RDW、NLR水平比较差异均无统计学意义（均P＞0.05），治疗后，2组PLR、RDW、NLR水平均明显低于治疗前，且观察组明显低于对照组，差异均有统计学意义（均P＜0.05）。观察组毒副反应发生率明显低于对照组［12.7%（7/55）比43.6%（24/55）］，差异有统计学意义（P＜0.05）。观察组随访2年后生存质量稳定率及改善率均明显高于对照组，差异均有统计学意义（P＜0.05）。结论  采用康艾注射液联合CapeOX化疗方案治疗结肠癌患者可改善临床效果，降低PLR、NLR、RDW水平，减少毒副反应，提高患者生存质量。

  
  

• Objective  To investigate the effect of Kang′ai injection combined with oxaliplatin+capecitabine （CapeOX） chemotherapy on patients with colon cancer and its impact on platelet/lymphocyte ratio (PLR), erythrocyte distribution width (RDW) and neutrophil/lymphocyte ratio (NLR). Methods From February 2015 to January 2018, 110 patients with colon cancer diagnosed by pathology in Department of Oncology, Tengzhou Central People′s Hospital, Shandong Province were selected. The patients were randomly divided into control group (55 cases) and observation group (55 cases). The control group was treated with CapeOX chemotherapy, and the observation group was treated with Kang′ai injection combined with CapeOX chemotherapy. The clinical efficacy, levels of PLR, RDW and NLR before and after treatment, toxic and side effects and quality of life 2 years after follow-up were compared between the two groups. Results  After treatment, the objective remission rate and disease control rate of the observation group were significantly higher than those of the control group ［49.1%(27/55) vs 27.3%(15/55), 81.8%(45/55) vs 63.6%(35/55)］(both P＜0.05). There were no significant differences in the levels of PLR, RDW and NLR between the two groups before treatment (all P＞0.05). After treatment, the levels of PLR, RDW and NLR of both groups were significantly lower than those before treatment, and those of the observation group were significantly lower than those of the control group (all P＜0.05). The incidence of toxic and side effects in the observation group was significantly lower than that in the control group ［12.7%(7/55) vs 43.6%(24/55)］(P＜0.05). After 2 years of follow-up, the stability rate and improvement rate of quality of life in the observation group were significantly higher than those in the control group (P＜0.05). Conclusion Kang′ai injection combined with CapeOX chemotherapy can improve the clinical efficacy in patients with colon cancer, decrease the levels of PLR, NLR and RDW, reduce toxic and side effects and improve the quality of life.